Jubilant Organosys has signed its second major CRAMS deal in a week. The company has signed a $33m, long-term contract with a US life sciences company. R Sankaraiah, Jubilant's Executive Director of Finance, said the company would book $250m orders in this year and $250m-$300m in the next three-four years.
Money Control
Tuesday, 31 August 2010
Jubilant signs $33m CRAMS deal
Lonza acquires Vivante
Lonza has purchased Vivante GMP Solutions to give it a foothold in the viral-based manufacturing market. Lonza said the acquisition advances its strategy to broaden its biologics custom service offering for the growing viral vaccine and gene therapy markets. Vivante, which is based in Houston, TX, produces GMP viral-based therapeutics.
Lonza
CMC adds disposable manufacturing
CMC Biologics has completed the addition of a state-of-the-art biopharmaceutical disposable manufacturing facility at its Seattle, WA site. CMC Biologics has partnered with Hyclone to supply the multi-purpose, single-use facility with processing equipment, including a 100L and two 500L single-use bioreactors and disposable mixers.
Genetic Engineering and Biotechnology News
Tuesday, 24 August 2010
Jubilant signs CRAMS deal
Jubilant Organosys has signed a $51m, four-year research and manufacturing deal with an unnamed US company. The company is in discussions to expand the contract, which could be extended by a further five years. R Sankaraiah, Jubilant's Executive Director of Finance, said the deal takes Jubilant;s CRAMS order book over $1bn.
Money Control
Thursday, 19 August 2010
Wednesday, 18 August 2010
Aesica invests in high containment
Aesica is investing £3m in a new high containment facility at its Queensborough, UK, site. The facility, which is due to be completed by May 2011, will enable Aesica to manufacture potent drugs typically classed as Safebridge category 3 and significantly extend its current capabilities in the formulation and packaging of liquid and solid dosage forms. In addition, the new facility will also include security measures that will ensure it can manufacture Schedule II controlled drugs such as opiates.
The Northern Echo
Tuesday, 17 August 2010
EMA and FDA plan joint inspections
The European Medicines Agency (EMA) and the US FDA are seeking potential candidate companies for a joint GMP inspection pilot programme for manufacturers of medicinal products. The agencies are hoping to see whether greater international collaboration can help to distribute inspection capacity allowing more manufacturing sites to be monitored and reducing unnecessary duplication.
EMA
Monday, 16 August 2010
Carbogen hinders Dishman
Dishman's Q1 turnover fell 12% to $43.2m. The company's CFO, VVS Murthy, put the fall down to reduced revenues at its Carbogen subsidiary. However, he expects Carbogen to see an overall 10% rise in sales over the full year.
Money Control
Thursday, 5 August 2010
Senator introduces safe drug manufacturing bill
US Senator, Michael Bennet, has introduced a bill, the US Drug Safety and Accountability Act of 2010, which aims to strengthen manufacturing quality standards, enhance the US FDA’s ability to track foreign manufacturing sites, and increase the authority of FDA to make drug product recalls. Socma welcomed the introduction of the bill and thanked the Senator for "introducing this common sense legislation which will strengthen the FDA and increase public health and safety by providing additional quality controls on drugs and their ingredients."
Senator Bennet
Socma
US consumers don't trust safety of foreign manufactured drugs
A survey conducted by the Pew Prescription Project has shown that US consumers do not trust the safety and freedom from contamination of drugs manufactured overseas. 78% of those polled trusted US made drugs, but only 6% trusted those made in China, 8% India and 30% Ireland. Swiss manufactured products were trusted by 47% and Canada made 60%.
Pharma Times
Ampac revenues rise in Q3
Ampac's fine chemicals businesses reported revenues of $20m in its Q3 ended June, compared to $15.6m in 2009, reflecting an increase in revenues from products in development. However, the operating loss for the quarter grew from $0.8m to $2.5m as a result of higher than anticipated costs associated with validating a process change for a core product and general manufacturing inefficiencies.
Ampac
Wednesday, 4 August 2010
AMRI revenues rise in Q2
Q2 revenues for AMRI's contract division rose 5% to $40.7m. The small scale manufacturing business revenues rose 1% to $8.2m and the large scale manufacturing revenues rose 10% to $21m.
AMRI
Pfenex awarded anthrax tech contract
The US Department of Health and Human Services has awarded Pfenex $18.8m contract to support the development of a robust Pfenex Expression Technology based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax. Pursuant to the contract, Pfenex will identify high producing expression strains capable of producing high titers of stable rPA and then develop commercial cGMP manufacturing process.
Xconomy
Cambrex sales fall
Q2 sales at Cambrex fell 4% to $57.4 million. Cambrex said the decrease is primarily due to lower demand for certain larger products including the effects of a supply chain disruption at a customer's facility, lower pricing on generic APIs and a renegotiated contract extension for certain drug delivery products resulting in lower pricing. However the company saw higher sales volume of controlled substances and generic APIs.
Outsourcing Pharma
Tuesday, 3 August 2010
DSM Pharma sales rise
DSM's Pharmaceutical Products business unit reported 5% sales growth in Q2 2010 compared to 2009. However, profit fell as a result of a challenging business environment and unfavourable product mix. DSM said the drop in results was somewhat compensated by the development of the US dollar.
DSM
Aesica raises £20m
Lloyds TSB Corporate Markets has provided £20m to Aesica Pharmaceuticals to support its continuing expansion through organic growth and acquisitions.
Pharmacy Business
Monday, 2 August 2010
SynCo to manufacture second product for Versartis
SynCo Bio Partners has extended its collaboration with Versartis, Inc. SynCo will scale-up a second manufacturing process on behalf of Versartis and provide fill and finish services for the manufacture, testing and release of formulated Drug Product vials.
Pharmaceutical Business Review
Aptuit partners with Siena
Siena Biotech has acquired a minority stake in Aptuit’s operations in Verona, Italy. In return, Aptuit will become the provider of choice for Siena’s development pipeline of compounds, focused in three key therapeutic areas, including Alzheimer’s disease, Huntington’s disease and oncology.
Mass High Tech
Fine chems sales rise at Albemarle
Sales for Albemarle's Fine Chemistry business rose 36% to $141.2m in Q2. The company said this was the result of increased volumes in both our performance chemicals and fine chemistry services businesses, and partly offset by product mix.
Business Week
Subscribe to:
Posts (Atom)
